Efficacy and safety profile of autologous blood versus talc pleurodesis for malignant pleural effusion: a randomized controlled trial.

abstract：:To investigate whether dry powder inhalers (DPIs) function in a constrained situation, a literature analysis was performed to evaluate the use of DPIs compared with established therapies in the treatment of acute asthma and COPD, irrespective of rapid-acting beta(2)-agonist used. The external databases Medline, Embase...

journal_title：Therapeutic advances in respiratory disease

authors： Selroos O,Borgström L,Ingelf J

更新日期：2009-04-01 00:00:00

abstract：BACKGROUND:Comorbidities probably contribute to the increased mortality observed among subjects with chronic obstructive pulmonary disease (COPD), but sex differences in the prognostic impact of comorbidities have rarely been evaluated in population-based studies. The aim of this study was to evaluate the impact of com...

journal_title：Therapeutic advances in respiratory disease

authors： Sawalha S,Hedman L,Backman H,Stenfors N,Rönmark E,Lundbäck B,Lindberg A

更新日期：2019-01-01 00:00:00

abstract：:Clinical and immunologic tolerance are hallmarks of successful allergen immunotherapy (AIT). Clinical benefits such as reduced symptoms, pharmacotherapy intake and improvement of quality of life persist following cessation of treatment. Successful AIT is associated with suppression of allergic inflammatory cells such ...

journal_title：Therapeutic advances in respiratory disease

authors： Kappen JH,Durham SR,Veen HI,Shamji MH

更新日期：2017-01-01 00:00:00

abstract：INTRODUCTION:Since its introduction to the market in 2016, selexipag has been an alternative oral therapy among both treatment-naïve patients and those with mono or dual therapy failure; however, limited information is available regarding the presentation and management of patients with pulmonary arterial hypertension ...

journal_title：Therapeutic advances in respiratory disease

authors： Highland KB,Hull M,Pruett J,Elliott C,Tsang Y,Drake W

更新日期：2019-01-01 00:00:00

abstract：:A major impediment in the development of novel drugs for chronic obstructive pulmonary disease (COPD) has been the scarcity of a well-validated, robust, and easily obtainable intermediate end point such as serum biomarkers. To date the best serum biomarkers in COPD have been non-speci"c pro-in"ammatory molecules synth...

journal_title：Therapeutic advances in respiratory disease

authors： Sin DD,Pahlavan PS,Man SF

更新日期：2008-04-01 00:00:00

abstract：:Increased inflammatory cytokines [such as tumor necrosis factor alpha (TNFα) and interleukin-6 (IL-6)] are observed in COVID-19 patients, especially in the severe group. The phenomenon of a cytokine storm may be the central inducer of apoptosis of alveolar epithelial cells, which leads to rapid progression in severe g...

journal_title：Therapeutic advances in respiratory disease

authors： Chen XY,Yan BX,Man XY

更新日期：2020-01-01 00:00:00

abstract：UNLABELLED:Alpha-1-antitrypsin deficiency [AATD] is associated with variable development of emphysema and other features of chronic obstructive pulmonary disease [COPD]. Matrix metalloproteinases [MMPs] are believed to be important in the pathophysiology of COPD, and may therefore confer susceptibility to this phenotyp...

journal_title：Therapeutic advances in respiratory disease

authors： McAloon CJ,Wood AM,Gough SC,Stockley RA

更新日期：2009-02-01 00:00:00

abstract：BACKGROUND:Proper adjustment of arterial oxygen saturation (SaO2) during daily activities in patients with interstitial lung disease (ILD) requiring long-term oxygen therapy is challenging. Given the multifactorial nature of the limited exercise tolerance in patients with ILDs, the isolated use of oxygen therapy may no...

journal_title：Therapeutic advances in respiratory disease

authors： Cuerpo S,Palomo M,Hernández-González F,Francesqui J,Albacar N,Hernández C,Blanco I,Embid C,Sellares J

更新日期：2020-01-01 00:00:00

abstract：BACKGROUND:N-chlorotaurine (NCT), a long-lived oxidant produced by human leukocytes, can be synthesized chemically and used topically as a well-tolerated antiseptic to different body regions including sensitive ones. The aim of this study was to test the tolerability of inhaled 1% NCT in aqueous solution upon repeated ...

journal_title：Therapeutic advances in respiratory disease

authors： Arnitz R,Stein M,Bauer P,Lanthaler B,Jamnig H,Scholl-Bürgi S,Stempfl-Al-Jazrawi K,Ulmer H,Baumgartner B,Embacher S,Geisler S,Gostner JM,Müllinger B,Kälz B,Nagl M

更新日期：2018-01-01 00:00:00

abstract：BACKGROUND:Endoscopic lung volume reduction coil (LVRC) treatment is a therapeutic option for selected patients with advanced emphysema. The effects and the safety of endoscopic lung volume reduction in patients with very low forced expired volume in one second (FEV1) remain to be determined. This study was conducted t...

journal_title：Therapeutic advances in respiratory disease

authors： Simon M,Harbaum L,Oqueka T,Kluge S,Klose H

更新日期：2018-01-01 00:00:00

abstract：OBJECTIVES:This study evaluated the effectiveness of behavioral interventions (brief counseling, nonspecific psychological support in groups - NSGS and cognitive behavioral group therapy - CBGT) in combination with bupropion SR for smoking cessation in the field, through a smoking cessation clinic. METHODS:Two-hundred...

journal_title：Therapeutic advances in respiratory disease

authors： Rovina N,Nikoloutsou I,Katsani G,Dima E,Fransis K,Roussos C,Gratziou C

更新日期：2009-12-01 00:00:00

abstract：BACKGROUND:Central airway obstruction (CAO) is a serious condition that affects patients with both benign and malignant diseases. Timely recognition of CAO is crucial for prompt intervention aimed at improving the symptoms and quality of life of these patients. The aim of this study is to evaluate the formal radiology ...

journal_title：Therapeutic advances in respiratory disease

authors： Harris K,Alraiyes AH,Attwood K,Modi K,Dhillon SS

更新日期：2016-04-01 00:00:00

abstract：:Angiogenesis is a driving force of a tumor's development. Targeting this process is an attractive option, as this is a feature shared by most of the solid tumors. A lot of antiangiogenic drugs have been developed following this path, including bevacizumab, sorafenib, sunitinib, vandetanib, ramucirumab, motesanib and m...

journal_title：Therapeutic advances in respiratory disease

authors： Caglevic C,Grassi M,Raez L,Listi A,Giallombardo M,Bustamante E,Gil-Bazo I,Rolfo C

更新日期：2015-08-01 00:00:00

abstract：OBJECTIVE:Severe exacerbations in alpha-1-antitrypsin (AAT)-deficient patients with chronic obstructive pulmonary disease (COPD) and/or emphysema are a major cause of hospitalization. A multicentre, observational, retrospective study was undertaken to evaluate the effect of continuous AAT augmentation therapy in reduci...

journal_title：Therapeutic advances in respiratory disease

authors： Barros-Tizón JC,Torres ML,Blanco I,Martínez MT,Investigators of the rEXA study group.

更新日期：2012-04-01 00:00:00

abstract：:Long-acting bronchodilators are the cornerstone of pharmacologic treatment of chronic obstructive pulmonary disease (COPD). Spiolto® or Stiolto® is a fixed-dose combination (FDC) containing two long-acting bronchodilators, the long-acting muscarinic receptor antagonist tiotropium (TIO) and the long-acting β2-adrenocep...

journal_title：Therapeutic advances in respiratory disease

authors： Derom E,Brusselle GG,Joos GF

更新日期：2019-01-01 00:00:00

abstract：:There is evidence of aberrations in the vitamin D-endocrine system in subjects with respiratory diseases. Vitamin D deficiency is highly prevalent in patients with respiratory diseases, and patients who receive vitamin D have significantly larger improvements in inspiratory muscle strength and maximal oxygen uptake. S...

journal_title：Therapeutic advances in respiratory disease

authors： Luong KV,Nguyen LT

更新日期：2013-12-01 00:00:00

abstract：BACKGROUND:Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is well known as a life-threatening condition during its clinical course. However, the clinical features and prognosis in AE of unclassifiable idiopathic interstitial pneumonia (AE-UCIIP) remain to be elucidated. The aim of this study was to clarif...

journal_title：Therapeutic advances in respiratory disease

authors： Enomoto N,Naoi H,Aono Y,Katsumata M,Horiike Y,Yasui H,Karayama M,Hozumi H,Suzuki Y,Furuhashi K,Fujisawa T,Inui N,Nakamura Y,Suda T

更新日期：2020-01-01 00:00:00

abstract：AIMS:The Cough Severity Diary (CSD) was developed in accordance with the FDA guidance for patient-reported outcome measures and is focused on capturing the patient's perception of cough in terms of frequency, intensity, and disruption due to their cough. The measure includes a series of seven items asking patients to r...

journal_title：Therapeutic advances in respiratory disease

authors： Martin Nguyen A,Bacci E,Dicpinigaitis P,Vernon M

更新日期：2020-01-01 00:00:00

abstract：:Pulmonary arterial hypertension (PAH) is a chronic condition of elevated pulmonary arterial pressures with associated increases in pulmonary vascular resistance leading to right ventricular failure, which was almost uniformly fatal prior to the introduction of pulmonary hypertension specific therapy. Systemic prostacy...

journal_title：Therapeutic advances in respiratory disease

authors： Stream AR,Bull TM

更新日期：2012-10-01 00:00:00

abstract：BACKGROUND:Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal interstitial lung disease (ILD). Currently, two antifibrotic drugs are available for reducing forced vital capacity (FVC) decline in IPF. However, many pulmonologists wait before initiating treatment, especially when IPF patients have stable dise...

journal_title：Therapeutic advances in respiratory disease

authors： Aono Y,Nakamura Y,Kono M,Nakamura H,Yokomura K,Imokawa S,Toyoshima M,Yasui H,Hozumi H,Karayama M,Suzuki Y,Furuhashi K,Enomoto N,Fujisawa T,Inui N,Suda T

更新日期：2020-01-01 00:00:00

abstract：:The issue of electronic cigarettes is one of the most controversial topics in public health. There is intense debate and dividing opinions about their use patterns, health effects and association with smoking. This is expected since they were only recently introduced to the market and they refer to a harm-reduction ap...

journal_title：Therapeutic advances in respiratory disease

authors： Farsalinos K

更新日期：2018-01-01 00:00:00

abstract：BACKGROUND:Bacterial pneumonia is a major cause of acute respiratory distress syndrome (ARDS) requiring extracorporeal membrane oxygenation (ECMO) support. However, it is unknown whether the type of pneumonia, community-acquired pneumonia (CAP) versus hospital-acquired pneumonia (HAP), should be considered when predict...

journal_title：Therapeutic advances in respiratory disease

authors： Park C,Na SJ,Chung CR,Cho YH,Suh GY,Jeon K

更新日期：2019-01-01 00:00:00

abstract：:Allergen-specific immunotherapy remains the most likely effective treatment modality for allergic disorders by targeting the underlying immune mechanisms and possibly causing modifications in the disease course, as well as treating the symptoms. Treatment and compliance experiences been gained over nearly a century in...

journal_title：Therapeutic advances in respiratory disease

authors： Ozdemir C

更新日期：2009-10-01 00:00:00

abstract：:Fluoroquinolones are commonly used to treat lung infections in patients with cystic fibrosis. These patients are susceptible to lung infection with common bacteria such as Staphylococcus aureus and Haemophilus influenzae, but are also prone to infection by opportunistic bacteria, including Pseudomonas aeruginosa. The ...

journal_title：Therapeutic advances in respiratory disease

authors： Hurley M,Smyth A

更新日期：2012-12-01 00:00:00

abstract：:Current guidelines for the management of chronic obstructive pulmonary disease (COPD) establish that bronchodilator medications are central to the symptomatic treatment of the disease. Regular treatment with long-acting bronchodilators is recommended as more effective and convenient than short-acting bronchodilators, ...

journal_title：Therapeutic advances in respiratory disease

authors： Brienza NS,Amor-Carro O,Ramos-Barbón D

更新日期：2011-02-01 00:00:00

abstract：:Bronchiectasis occurs as a result of a vicious circle consisting of an impaired mucociliary transport system, inflammation, and infection and repair of the airways. Damage to the mucociliary system prevents secretion elimination and facilitates bacterial growth and bronchial inflammation. To facilitate mucociliary cle...

journal_title：Therapeutic advances in respiratory disease

authors： Máiz Carro L,Martínez-García MA

更新日期：2019-01-01 00:00:00

abstract：BACKGROUND:Pseudomonas aeruginosa (Pa) is the predominant pulmonary pathogen in patients with cystic fibrosis (CF). Tobramycin nebulization is used for the eradication of Pa infection. Nowadays, tobramycin dry powder inhalation (DPI) is available as well. This study reports the results of eradicating Pa with tobramycin...

journal_title：Therapeutic advances in respiratory disease

authors： Akkerman-Nijland AM,Yousofi M,Rottier BL,Van der Vaart H,Burgerhof JGM,Frijlink HW,Touw DJ,Koppelman GH,Akkerman OW

更新日期：2020-01-01 00:00:00

abstract：RATIONALE:Symptom relief is a key treatment goal in patients with chronic obstructive pulmonary disease (COPD). However, there are limited data available on the response to bronchodilator therapy in patients at low risk of exacerbations with different levels of symptom severity. This study compared treatment responses ...

journal_title：Therapeutic advances in respiratory disease

authors： Vogelmeier CF,Kerwin EM,Bjermer LH,Tombs L,Jones PW,Boucot IH,Naya IP,Lipson DA,Compton C,Barnes N,Maltais F

更新日期：2020-01-01 00:00:00

abstract：OBJECTIVE:Our aim was to determine the influence of pulmonary rehabilitation conducted in therapeutic salt mine chambers on the functional fitness of older adults. METHODS:The study included 22 individuals of age >65 years with chronic respiratory conditions. The patients underwent the Fullerton test before and after ...

journal_title：Therapeutic advances in respiratory disease

authors： Mętel S,Kostrzon M,Adamiak J,Gattner H,Kościelecka D,Sosulska A,Szczygieł E,Golec J

更新日期：2020-01-01 00:00:00

abstract：OBJECTIVES:To describe the health-related quality of life (HRQL) in a cohort of COPD patients recruited in primary care and identify the variables of the patients and the treatment associated with impaired HRQL. METHOD:Multicenter, observational study of patients with COPD recruited in Primary Care centers. Data regar...

journal_title：Therapeutic advances in respiratory disease

authors： Miravitlles M,Molina J,Naberan K,Cots JM,Ros F,Llor C,EVOCA study.

更新日期：2007-12-01 00:00:00